We have shown in several ways that FRRS1, CTRAM, SCGB3A1, FAM92B/CIBAR2, and TMEFF2 are convincing candidates to further investigate as potential drug targets for AD. This evidence concerns the gene CIBAR2 and Alzheimer disease.